Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Fate Therapeutics

General information

Main focus: Allogeneic natural killer cell therapies

Company stage: Clinical

Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:FATE)

Location: San Diego, CA, USA



Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta

Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.


HashtagFate Therapeutics, Inc.

Company: Fate Therapeutics
Search CRISPR Medicine